Argo Wealth Advisory LLC Acquires Shares of 3,245 McKesson Corporation $MCK

Key Points

• Argo Wealth Advisory LLC bought 3,245 shares of McKesson in Q4 worth about $2.66 million, equal to ~1.6% of its portfolio and its 21st largest holding, and institutional investors now own roughly 85.07% of the stock.
• Insider selling has increased: EVP Michele Lau sold 2,725 shares at an average of $990 (~$2.70M) and insiders have sold 3,592 shares worth $3.52M in the past 90 days, while corporate insiders hold only 0.08% of shares.
• Analysts remain positive with a "Moderate Buy" consensus (13 Buys, 3 Holds) and a $970.93 target vs. the stock trading near $868, after McKesson slightly beat quarterly EPS/revenue estimates and issued FY2026 EPS guidance of $38.80–$39.20.

Argo Wealth Advisory LLC purchased a new position in McKesson Corporation (NYSE:MCK - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 3,245 shares of the company's stock, valued at approximately $2,662,000. McKesson accounts for approximately 1.6% of Argo Wealth Advisory LLC's investment portfolio, making the stock its 21st largest holding.

Several other hedge funds have also recently modified their holdings of the business. GGM Financials LLC purchased a new stake in McKesson during the third quarter valued at approximately $25,000. State of Wyoming purchased a new position in shares of McKesson in the second quarter worth $29,000. Hopwood Financial Services Inc. acquired a new stake in shares of McKesson in the third quarter worth $31,000. Vermillion & White Wealth Management Group LLC acquired a new stake in shares of McKesson in the third quarter worth $33,000. Finally, Board of the Pension Protection Fund acquired a new stake in shares of McKesson in the fourth quarter worth $33,000. Hedge funds and other institutional investors own 85.07% of the company's stock.

Insider Activity

In related news, EVP Michele Lau sold 2,725 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $990.00, for a total value of $2,697,750.00. Following the sale, the executive vice president directly owned 3,247 shares of the company's stock, valued at approximately $3,214,530. This represents a 45.63% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Maria Martinez sold 349 shares of the stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $939.87, for a total transaction of $328,014.63. Following the completion of the sale, the director directly owned 301 shares in the company, valued at approximately $282,900.87. The trade was a 53.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,592 shares of company stock worth $3,518,555 in the last 90 days. Corporate insiders own 0.08% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on MCK shares. Morgan Stanley restated an "overweight" rating and set a $966.00 price target on shares of McKesson in a research report on Thursday, January 29th. JPMorgan Chase & Co. increased their price objective on shares of McKesson from $983.00 to $1,107.00 and gave the company an "overweight" rating in a report on Tuesday, February 10th. Evercore reissued an "outperform" rating on shares of McKesson in a research note on Thursday, March 5th. Raymond James Financial set a $970.00 price target on shares of McKesson in a research note on Thursday, March 5th. Finally, Bank of America reduced their target price on shares of McKesson from $1,040.00 to $1,000.00 and set a "buy" rating on the stock in a research note on Monday, April 6th. Thirteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $970.93.

McKesson Stock Performance

Shares of MCK stock opened at $868.08 on Friday. McKesson Corporation has a fifty-two week low of $637.00 and a fifty-two week high of $999.00. The stock has a market capitalization of $106.33 billion, a P/E ratio of 24.97, a price-to-earnings-growth ratio of 1.25 and a beta of 0.42. The company has a 50 day moving average price of $915.83 and a 200 day moving average price of $853.64.

McKesson (NYSE:MCK - Get Free Report) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, topping the consensus estimate of $9.19 by $0.15. The company had revenue of $106.16 billion during the quarter, compared to analysts' expectations of $105.98 billion. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. The firm's revenue was up 11.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $8.03 EPS. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. On average, research analysts forecast that McKesson Corporation will post 32.77 EPS for the current fiscal year.

McKesson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, April 1st. Shareholders of record on Monday, March 2nd were given a dividend of $0.82 per share. The ex-dividend date was Monday, March 2nd. This represents a $3.28 dividend on an annualized basis and a yield of 0.4%. McKesson's dividend payout ratio is presently 9.43%.

McKesson Company Profile

McKesson Corporation NYSE: MCK is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company's core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.

Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Corporation (NYSE:MCK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.